Automate Your Wheel Strategy on HAE
With Tiblio's Option Bot, you can configure your own wheel strategy including HAE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HAE
- Rev/Share 27.9779
- Book/Share 18.3388
- PB 2.8966
- Debt/Equity 1.3882
- CurrentRatio 1.7184
- ROIC 0.0824
- MktCap 2559178176.0
- FreeCF/Share 3.9318
- PFCF 13.5288
- PE 15.6465
- Debt/Assets 0.4975
- DivYield 0
- ROE 0.1873
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | HAE | Raymond James | Strong Buy | Outperform | -- | $78 | Aug. 11, 2025 |
| Reiterated | HAE | Barrington Research | -- | Outperform | $95 | $86 | Aug. 8, 2025 |
| Downgrade | HAE | JP Morgan | Overweight | Neutral | -- | $62 | Aug. 8, 2025 |
| Upgrade | HAE | Citigroup | Neutral | Buy | -- | $90 | July 9, 2025 |
| Initiation | HAE | Robert W. Baird | -- | Outperform | -- | $87 | June 26, 2025 |
| Downgrade | HAE | BofA Securities | Neutral | Underperform | $95 | $68 | Feb. 7, 2025 |
| Initiation | HAE | JP Morgan | -- | Overweight | -- | $116 | Dec. 6, 2024 |
| Initiation | HAE | CL King | -- | Buy | -- | $116 | Sept. 13, 2024 |
| Initiation | HAE | BofA Securities | -- | Neutral | -- | $85 | Sept. 11, 2024 |
| Initiation | HAE | BTIG Research | -- | Buy | -- | $112 | Sept. 10, 2024 |
News
I'm Recommending Haemonetics Again, But With Caveats (Ratings Upgrade)
Published: August 11, 2025 by: Seeking Alpha
Sentiment: Positive
Haemonetics Corporation remains a high-quality blood-management franchise with strong TEG and plasma software moats, but recent growth has paused due to portfolio shifts and competition. Q1 FY2026 results beat expectations on margins and cash flow, but headline revenue declined due to deliberate exits and one-time factors boosting growth. HAE valuation is compelling at ~11x forward EPS and ~8x EV/EBITDA, with strong FCF and margin expansion offering attractive upside if execution improves.
Read More
Understanding Haemonetics (HAE) Reliance on International Revenue
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Evaluate Haemonetics' (HAE) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Read More
These Analysts Slash Their Forecasts On Haemonetics After Q1 Results
Published: August 08, 2025 by: Benzinga
Sentiment: Negative
Haemonetics Corp HAE reported upbeat earnings for the first quarter on Thursday.
Read More
Haemonetics (HAE) Reports Q1 Earnings: What Key Metrics Have to Say
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Haemonetics (HAE) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Unlocking Q1 Potential of Haemonetics (HAE): Exploring Wall Street Estimates for Key Metrics
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Beyond analysts' top-and-bottom-line estimates for Haemonetics (HAE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
Read More
Analysts Estimate Haemonetics (HAE) to Report a Decline in Earnings: What to Look Out for
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Negative
Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
HAE Stock Gains on Q4 Earnings and Revenue Beat, Margins Up
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Haemonetics' fourth-quarter fiscal 2025 results reflect the positive impact of its long-term plan, with meaningful earnings growth and margin expansion.
Read More
Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website
Published: May 08, 2025 by: PRNewsWire
Sentiment: Neutral
Financial release accessible online BOSTON , May 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter and fiscal year 2025, which ended March 29, 2025, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m.
Read More
4 MedTech Stocks Poised to Outshine Q1 Earnings Estimates
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
MedTech companies' quarterly results are likely to reflect base business recovery on a year-over-year basis. Let's see how HIMS, GMED, QDRL and HAE are poised ahead of their earnings release.
Read More
Is it Apt to Retain HAE Stock in Your Portfolio for Now?
Published: March 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Strong prospects for the Hospital Business and the robust NexSys PCS system bode well for Haemonetics.
Read More
Haemonetics to Present at Raymond James 46th Annual Institutional Investors Conference
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral
BOSTON , Feb. 24, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 46th Annual Institutional Investors Conference on Tuesday, March 4, 2025 at 2:50 p.m. ET. The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link: https://wsw.com/webcast/rj131/hae/1437678.
Read More
About Haemonetics Corporation (HAE)
- IPO Date 1991-05-10
- Website https://www.haemonetics.com
- Industry Medical - Instruments & Supplies
- CEO Christopher A. Simon
- Employees 3657